FDA Approves Cholera Vaccine for U.S. Travelers

FDA Approves Cholera Vaccine for U.S. Travelers
Share on FacebookTweet about this on TwitterShare on LinkedIn

MONDAY, June 13, 2016 (HealthDay News) — The first vaccine to protect American travelers from cholera has been approved by the U.S. Food and Drug Administration.

The liquid vaccine Vaxchora was approved for adults ages 18 to 64 who are traveling to countries affected by cholera, the Associated Press reported.

The FDA’s approval of the vaccine is based on four clinical trials that included a total of 3,797 people. Ninety-three and 90 percent of participants produced antibodies indicative of protection against cholera in the 18 through 45 and 46 through 64 age groups, respectively. Common side effects included abdominal pain, diarrhea, headache, and fatigue, the AP reported.

“The approval of Vaxchora represents a significant addition to the cholera-prevention measures currently recommended by the U.S. Centers for Disease Control and Prevention for travelers to cholera-affected regions,” Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, said in a statement.

More Information

Copyright © 2016 HealthDay. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

five + ten =